The human CSF pain proteome.


Journal

Journal of proteomics
ISSN: 1876-7737
Titre abrégé: J Proteomics
Pays: Netherlands
ID NLM: 101475056

Informations de publication

Date de publication:
06 01 2019
Historique:
received: 31 01 2018
revised: 27 04 2018
accepted: 20 05 2018
pubmed: 1 6 2018
medline: 23 2 2020
entrez: 1 6 2018
Statut: ppublish

Résumé

Chronic pain represents one of the major medical challenges in the 21st century, affecting >1.5 billion of the world population. Overlapping and heterogenous symptoms of various chronic pain conditions complicate their diagnosis, emphasizing the need for more specific biomarkers to improve the diagnosis and understand the disease mechanisms. We have here investigated proteins found in human CSF with respect to known "pain" genes and in a cohort of patients with dysfunctional pain (fibromyalgia, FM), inflammatory pain (rheumatoid arthritis patients, RA) and non-pain controls utilized semi-quantitative proteomics using mass spectrometry (MS) to explore quantitative differences between these cohorts of patients. We found that "pain proteins" detected in CSF using MS are typically related to synaptic transmission, inflammatory responses, neuropeptide signaling- and hormonal activity. In addition, we found ten proteins potentially associated with chronic pain in FM and RA: neural cell adhesion molecule L1, complement C4-A, lysozyme C, receptor-type tyrosine-protein phosphatase zeta, apolipoprotein D, alpha-1-antichymotrypsin, granulins, calcium/calmodulin-dependent protein kinase type II subunit alpha, mast/stem cell growth factor receptor Kit, prolow-density lipoprotein receptor-related protein 1. These proteins might be of importance for understanding the mechanisms of dysfunctional/inflammatory chronic pain and also for use as potential biomarkers. SIGNIFICANCE: Chronic pain is a common disease and it poses a large burden on worldwide health. Fibromyalgia (FM) is a heterogeneous disease of unknown etiology characterized by chronic widespread pain (CWP). The diagnosis and treatment of FM is based on the analysis of clinical assessments and no measurable biomarkers are available. Cerebrospinal fluid (CSF) has been historically considered as a rich source of biomarkers for diseases of nervous system including chronic pain. Here, we explore CSF proteome of FM patients utilizing mass spectrometry based quantitative proteomics method combined with multivariate data analysis in order to monitor the dynamics of the CSF proteome. Our findings in this exploratory study support notable presence of pain related proteins in CSF yet with specific domains including inflammatory responses, neuropeptide signaling- and hormonal activity. We have investigated molecular functions of significantly altered proteins and demonstrate presence of 176 known pain related proteins in CSF. In addition, we found ten proteins potentially associated with pain in FM and RA: neural cell adhesion molecule L1, complement C4-A, lysozyme C, receptor-type tyrosine-protein phosphatase zeta, apolipoprotein D, alpha-1-antichymotrypsin, granulins, calcium/calmodulin-dependent protein kinase type II subunit alpha, mast/stem cell growth factor receptor Kit, prolow-density lipoprotein receptor-related protein 1. These proteins are novel in the context of FM but are known to be involved in pain mechanisms including inflammatory response and signal transduction. These results should be of clear significance and interest for researchers and clinicians working in the field of pain utilizing human CSF and MS based proteomics.

Identifiants

pubmed: 29852297
pii: S1874-3919(18)30224-0
doi: 10.1016/j.jprot.2018.05.012
pii:
doi:

Substances chimiques

Biomarkers 0
Cerebrospinal Fluid Proteins 0
Proteome 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

67-76

Informations de copyright

Copyright © 2018 Elsevier B.V. All rights reserved.

Auteurs

Payam Emami Khoonsari (PE)

Department of Medical Sciences, Clinical Chemistry, Uppsala University, Sweden; Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden.

Elena Ossipova (E)

Unit of Rheumatology, Department of Medicine, Rheumatology Clinic, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.

Johan Lengqvist (J)

Unit of Rheumatology, Department of Medicine, Rheumatology Clinic, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.

Camilla I Svensson (CI)

Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden.

Eva Kosek (E)

Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.

Diana Kadetoff (D)

Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.

Per-Johan Jakobsson (PJ)

Unit of Rheumatology, Department of Medicine, Rheumatology Clinic, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.

Kim Kultima (K)

Department of Medical Sciences, Clinical Chemistry, Uppsala University, Sweden.

Jon Lampa (J)

Unit of Rheumatology, Department of Medicine, Rheumatology Clinic, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden. Electronic address: jon.lampa@ki.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH